Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Celldex Therapeutics Inc. Shares Tumbled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Celldex Therapeutics (NASDAQ: CLDX  ) , a predominantly clinical-stage biopharmaceutical company focused on developing immunotherapeutic solutions for cancer and other difficult-to-treat diseases, dipped as much as 12% after fourth-quarter earnings results were released before the opening bell this morning.

So what: For the quarter, Celldex reported just $0.6 million in revenue, down 85% from the year-ago period due to a decrease in royalty revenue recognized from Rotarix (there's a tongue twister for you!). The company's net loss, however, was no laughing matter as it shrank noticeably to just $22.1 million, or $0.27 per share, from $81.6 million, or $1.02 per share, in the year-ago period. By comparison, Celldex's loss came in $0.01 per sharenarrower than expected. Celldex noted that it ended the year with $303 million in cash and cash equivalents, which is believed to be enough to fund company operations through fiscal 2016. It also said it anticipates beginning another four clinical studies, on top of the five already ongoing, throughout fiscal 2014.

Now what: This looks like a cut-and-dried case of buy the rumor, sell the news. Celldex's report was better than Wall Street anticipated on a number of accounts, but when all is said and done investors are paying nearly $2.2 billion for a company that is basically clinical in nature. If just a few of these pipeline products fail to meet their endpoints, Celldex's share price could be hit pretty hard. This isn't to say that immuno-oncology therapies aren't all the rage of Wall Street, because they are! However, looking at this reasonably, Celldex is going to need exceptional data and a perfect drug launch to  maintain its current valuation, which to me seems highly unlikely.

Celldex shares have soared over the past year, but even it may struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 03, 2014, at 3:09 PM, Hope4GoodFuture wrote:

    Maybe the fact that they announced the discontinuation of one of they programs had something to do with the drop.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2862017, ~/Articles/ArticleHandler.aspx, 8/30/2015 6:17:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
CLDX $15.36 Up +0.25 +1.65%
Celldex Therapeuti… CAPS Rating: ****